Comparative Pharmacology
Head-to-head clinical analysis: GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE versus MUCINEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE versus MUCINEX.
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE vs MUCINEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Guaifenesin is an expectorant that increases respiratory tract fluid secretions, reducing mucus viscosity. Dextromethorphan is a centrally acting cough suppressant that binds to NMDA receptors and sigma-1 receptors, elevating the cough threshold.
Guaifenesin is an expectorant that increases respiratory tract fluid secretion and reduces mucus viscosity, facilitating its removal.
For adults and children ≥12 years: 10 mL (200 mg guaifenesin, 20 mg dextromethorphan) orally every 4 hours, not to exceed 60 mL (1200 mg guaifenesin, 120 mg dextromethorphan) per 24 hours.
600 mg orally twice daily (extended-release); for immediate-release: 200 mg orally three times daily or 400 mg orally twice daily.
None Documented
None Documented
Guaifenesin: 1-2 hours; Dextromethorphan: 3-6 hours (extensive metabolizers), 18-24 hours (poor metabolizers due to CYP2D6 polymorphism).
1-2 hours (terminal elimination half-life); clinical context: rapid clearance requires frequent dosing to maintain mucolytic effect.
Guaifenesin: ~60% renal (metabolites), ~35% fecal; Dextromethorphan: ~70% renal (parent and metabolites, 45% as unchanged dextrorphan), ~20% biliary/fecal.
Renal: approximately 50-60% as unchanged drug (guaifenesin) and metabolites; minor biliary/fecal elimination (<10%).
Category C
Category C
Expectorant/Antitussive Combination
Expectorant